APR TD012 - Hailey Hailey Disease

APR TD012

Hailey Hailey Disease

APR TD012 is a clinical stage drug candidate for the treatment of wounds in Hailey Hailey Disease (HHD) patients. The product improves healing process thanks to its bioburden control and its anti-oxidant properties.

Oxidative stress has been demonstrated to play a specific role in the pathogenesis of HHD by regulating the expression of factors playing an important role in keratinocyte proliferation and differentiation.

Preliminary pre-clinical data suggest that our product could be able to shift the oxidation reduction (redox) balance, leading to a protective antioxidant response.

In addition, thanks to Hypochlorous acid (HClO) presence APR-TD012 could exert a strong antimicrobial activity inactivating one of the most common causes of skin infections in the HHD lesions, which is Staphylococcus aureus.

TEHCLO® TECHNOLOGY

Tehclo™ is the globally patented nanotechnology platform applied to the production of unique hypochlorous acid solutions that ensures the most consistent quality for best-in-class clinical outcomes.

The nanotechnology applied drives electrolysis using a current several times stronger than other standard electrolysis process, minimizing chloride requirements and producing acid oxidizing solution with >95% hypochlorous acid (HClO) purity and 0% hypochlorite (OCl^-) as well as the lowest pH range (2.5-3.0) and high ORP (>1100 mv).